Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Treatment of reaction to red tattoo ink with intralesional triamcinolone
Wambier, Carlos Gustavo , Cappel, Mark A. , Wambier, Sarah Perillo de Farias , Cappel, Mark Aaron, Wambier, Carlos G

Mayo Clinic

Anais Brasileiros de Dermatologia | November 15, 2017 | Volume: 92 | Issue: 5 | Pages: 748-750

10.1590/abd1806-4841.20176678 | PMID 29166529 Get It

Impact of Diabetes Mellitus on Outcomes in Patients Supported With Left Ventricular Assist Devices
Briasoulis, Αlexandros , Schettle, Sarah , Tchantchaleishvili, Vakhtang , Pereira, Naveen L. , Edwards, Brooks S., Clavell, Alfredo L. , Maltais, Simon, Joyce, David L. , Joyce, Lyle D., Daly, Richard C. , Kushwaha, Sudhir S. , Stulak, John M., Asleh, Rabea , Briasoulis, Alexandros, Schettle, Sarah D., Briasoulis, Alexandros , Tchantchaleishvili, Vakhtang

Mayo Clinic

Circulation: Heart Failure | November 15, 2017 | Volume: 10 | Issue: 11 | Pages: No page available

10.1161/circheartfailure.117.004213 | PMID 29141856 Get It

Background Diabetes mellitus (DM) is a risk factor for morbidity and mortality in patients with heart failure. The effect of DM on post–left ventricular assist device (LVAD) implantation outcomes is unclear. This study sought to investigate whether patients with DM had worse outcomes than patients without DM after LVAD implantation and whether LVAD support resulted in a better control of DM. Methods and Results We retrospectively reviewed 341 consecutive adults who underwent implantation of LVAD from 2007 to 2016. Patient characteristics and adverse events were studied and compared between patients with and without DM. One hundred thirty-one patients (38%) had DM. Compared with patients without DM, those with DM had higher rates of ischemic cardiomyopathy, LVAD implantation as destination therapy, and increased baseline body mass index. In a proportional hazards (Cox) model with adjustment for relevant covariates and median follow-up of 16.1 months, DM was associated with increased risk of all-cause mortality (hazard ratio, 1.73; 95% confidence interval: 1.18–2.53; P =0.005) and increased risk of nonfatal LVAD-related complications, including a composite of stroke, pump thrombosis, and device infection (hazard ratio, 2.1; 95% confidence interval: 1.35–3.18; P =0.001). Preoperative hemoglobin A1c was not significantly associated with mortality or adverse events among patients with DM. LVAD implantation resulted in a remarkable decrease in hemoglobin A1c levels (7.4±1.9 pre-LVAD versus 6.0±1.5 and 6.3±1.4 after 3 and 12 months post-LVAD, respectively; P <0.0001) and a significant reduction in requirements of DM medications. Conclusions DM is associated with increased rates of all-cause mortality and major adverse events despite favorable glycemic control after LVAD implantation.
Myocardial Cobalt Levels Are Elevated in the Setting of Total Hip Arthroplasty
Wright, Thomas C., Bois, Melanie C. , Amin, Md Shahrier , Fayyaz, Ahmed, Jenkins, Sarah M. , Wyles, Saranya P. , Day, Patrick L. , Murray, David , Trousdale, Robert T. , Anavekar, Nandan S., Edwards, William D. , Maleszewski, Joseph J. , Wyles, Cody C. , Wright, T. Carson, Day, Patrick

Mayo Clinic

Journal of Bone and Joint Surgery | November 15, 2017 | Volume: 99 | Issue: 22 | Pages: e118

10.2106/jbjs.17.00159 | PMID 29135673 Get It

Background: Arthroplasty implants commonly contain elemental metal that may undergo wear-related release. Recently, cases of hip implant-associated myocardial injury have been reported. However, we are not aware of any previous study that has systematically measured myocardial metal levels or examined the relationship with total hip arthroplasty (THA). Methods: Archives of our institution were queried for autopsies of individuals who had undergone THA between 1990 and 2013. Myocardial tissue samples were analyzed for cobalt (Co) and chromium (Cr) levels with inductively coupled plasma mass spectroscopy. Seventy-five Co/Cr-on-polyethylene THA cases were included (mean age at time of death = 77.4 years; 49% women) as were 73 non-arthroplasty controls matched for age, sex, and history of hypertension and diabetes mellitus. Results: Significantly higher median myocardial concentrations of Co were observed in individuals with THA compared with controls (0.12 versus 0.06 μg/g, p < 0.0001). The median Co concentration was 69% higher in patients who had undergone THA revision (0.169 μg/g) than in those who underwent primary THA (0.100 μg/g; p = 0.004). In general, higher Co levels were observed in those with multiple replaced joints, although this finding only trended toward significance. Cardiomegaly, interstitial fibrosis, and decreased ejection fraction were observed more frequently in the postmortem samples of patients with implants than in those of controls (p = 0.0002, 0.044, and 0.0039, respectively). Conclusions: We believe this to be the first study to quantify metal levels in cardiac tissue in patients with and without joint replacement. The elevated Co levels, in concert with cardiomegaly and increased interstitial fibrosis found during autopsy, in the arthroplasty cohort are novel, important findings. Although Co levels were significantly elevated above those in controls, the majority were below those seen in clinical case reports of death from Co cardiotoxicity associated with metal-on-metal prostheses. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder
Amare, Azmeraw T. , Schubert, Klaus Oliver , Clark, Scott R. , Papiol, Sergi , Heilbronner, Urs , Degenhardt, Franziska , Tekola‐Ayele, Fasil , Hsu, Yi‐Hsiang , Shekhtman, Tatyana , Adli, Mazda , Akula, Nirmala , Akiyama, Kazufumi , Ardau, Raffaella , Arias, Bárbara , Aubry, Jean‐Michel , Bhattacharjee, Abesh Kumar, Benabarre, Antonio , Bengesser, Susanne , Birner, Armin , Brichant‐Petitjean, Clara, Cervantes, Pablo , Chen, Hsi‐Chung , Chillotti, Caterina , Cichon, Sven , Cruceanu, Cristiana , Czerski, Piotr M. , Dalkner, Nina , Zompo, Maria Del , Étain, Bruno , Falkai, Peter , Forstner, Andreas J. , Frisén, Louise , Frye, Mark A. , Fullerton, Janice M. , Gard, Sébastien, Grigoroiu‐Serbânescu, Maria , Grof, Paul , Hashimoto, Ryota , Jamain, Stéphane , Jiménez, Esther , Kahn, Jean‐Pierre, Kassem, Layla, Kuo, Po‐Hsiu , Kato, Tadafumi , Kittel‐Schneider, Sarah , Kliwicki, Sebastian , Laje, Gonzalo, Landén, Mikael , Lavebratt, Catharina , Leboyer, Marion , Leckband, Susan G. , Tortorella, Alfonso , Manchia, Mirko , Martinsson, Lina , McCarthy, Michael J. , Mitjans, Marina , Mondimore, Francis M. , Nöthen, Markus M. , Novák, Tomáš , O’Donovan, Claire , Ozaki, Norio , Ösby, Urban, Pfennig, Andrea , Potash, James B. , Reif, Andreas , Reininghaus, Eva Z. , Schalling, Martin , Schofield, Peter R. , Schweizer, Barbara , Severino, Giovanni , Shilling, Paul D. , Shimoda, Katzutaka, Simhandl, Christian , Slaney, Claire , Stamm, Thomas , Stopková, Pavla , Maj, Mario , Turecki, Gustavo , Vieta, Eduard , Volkert, Julia, Zandi, Peter P. , Bauer, Michael , Alda, Martin , McMahon, Francis J. , Etain, B , Vieta, E , Schofield, Peter R , Cichon, Sven , Nöthen, Markus M , Alda, Martin , Fullerton, Janice M , Hou, Liping , Backlund, Lena , Bellivier, Frank , Biernacka, Joanna M. , Dalkner, Nina , Dayer, Alexandre G. , DePaulo, J Raymond , Garnham, Julie , Goes, Fernando , Hauser, Joanna , Herms, Stefan , Hoffmann, Per , Hofmann, Andrea , Kelsoe, John R , König, Barbara , Kusumi, Ichiro , McElroy, Susan L. , Colom, Francesc , Monteleone, Palmiero , Nievergelt, Caroline M , Reininghaus, Eva , Rouleau, Guy Armand , Rybakowski, Janusz K , Squassina, Alessio , Witt, Stephanie H. , Wright, A. Jordan , Mitchell, Philip B , Rietschel, Marcella , Schulze, Thomas , Baune, Bernhard , Amare, Azmeraw , Papiol, Sergi , Heilbronner, Urs , Chen, Hsi-Chung , Cruceanu, Cristiana , Czerski, Piotr , Jamain, Stéphane , Grigoroiu-Serbanescu, Maria , Kuo, Po-Hsiu , Kittel-Schneider, Sarah , Lavebratt, Catharina , Leboyer, Marion , Tortorella, Alfonso , McCarthy, Michael , Novak, Tomas , Reif, Andreas , Stopkova, Pavla , Turecki, Gustavo , McMahon, Francis , Arias, Bárbara , Hashimoto, Ryota , Ozaki, Norio , Schubert, Klaus Oliver , Kato, Tadafumi , Mitjans, Marina , Manchia, Mirko

Mayo Clinic

JAMA Psychiatry | November 15, 2017 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamapsychiatry.2017.3433 | PMID 29121268 Get It

ICare-ACS (Improving Care Processes for Patients With Suspected Acute Coronary Syndrome)
Than, Martin , Pickering, John W. , Dryden, Jeremy M., Lord, Sally J., Aldous, Sally, Allan, Kate , Ardagh, Michael, Bonning, John , Callender, Rosie, Chapman, Laura R.E., Christiansen, J., Cromhout, Andre P.J., Cullen, Louise , Deely, Joanne M., Devlin, Gerard, Ferrier, Katherine, Florkowski, Christopher M , Frampton, Christopher , George, Peter M., Hamilton, Gregory J. , Jaffe, Allan S. , Makower, R M, Matthews, Timothy James , Parsonage, William , Pelt, Niels C van, Poynton, Louise, Richards, Mark , Scott, Anthony, Simmonds, Mark, Smyth, David, Thomas, Oliver P., To, Andrew, Toit, Stephen A. Du, Troughton, Richard W. , Yates, Kim , Lord, Sarah J. , Cullen, Louise , Aitken, Stuart A. , Chapman, Laura , Jaffe, Allan S. , Kerr, Andrew Jensen , Larkin, Gregory Luke , Peacock, William Frank , Peckler, Brad , Toit, Stephen Du , Troughton, Richard W , Lord, Sarah J , Richards, Arthur M , Than, Martin , Pickering, John W

Mayo Clinic

Circulation | November 15, 2017 | Volume: 137 | Issue: 4 | Pages: 354-363

10.1161/circulationaha.117.031984 | PMID 29138293 Get It

Background: Efforts to safely reduce length of stay for emergency department patients with symptoms suggestive of acute coronary syndrome (ACS) have had mixed success. Few system-wide efforts affecting multiple hospital emergency departments have ever been evaluated. We evaluated the effectiveness of a nationwide implementation of clinical pathways for potential ACS in disparate hospitals. Methods: This was a multicenter pragmatic stepped-wedge before-and-after trial in 7 New Zealand acute care hospitals with 31 332 patients investigated for suspected ACS with serial troponin measurements. The implementation was a clinical pathway for the assessment of patients with suspected ACS that included a clinical pathway document in paper or electronic format, structured risk stratification, specified time points for electrocardiographic and serial troponin testing within 3 hours of arrival, and directions for combining risk stratification and electrocardiographic and troponin testing in an accelerated diagnostic protocol. Implementation was monitored for >4 months and compared with usual care over the preceding 6 months. The main outcome measure was the odds of discharge within 6 hours of presentation Results: There were 11 529 participants in the preimplementation phase (range, 284–3465) and 19 803 in the postimplementation phase (range, 395–5039). Overall, the mean 6-hour discharge rate increased from 8.3% (range, 2.7%–37.7%) to 18.4% (6.8%–43.8%). The odds of being discharged within 6 hours increased after clinical pathway implementation. The odds ratio was 2.4 (95% confidence interval, 2.3–2.6). In patients without ACS, the median length of hospital stays decreased by 2.9 hours (95% confidence interval, 2.4–3.4). For patients discharged within 6 hours, there was no change in 30-day major adverse cardiac event rates (0.52% versus 0.44%; P =0.96). In these patients, no adverse event occurred when clinical pathways were correctly followed. Conclusions: Implementation of clinical pathways for suspected ACS reduced the length of stay and increased the proportions of patients safely discharged within 6 hours. Clinical Trial Registration: URL: https://www.anzctr.org.au/ (Australian and New Zealand Clinical Trials Registry). Unique identifier: ACTRN12617000381381.
Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer
Kosari, Farhad , Karnes, R. Jeffrey , Nasir, Aqsa , Johnson, Sarah H. , Gaitatzes, Athanasios , Smadbeck, James B. , Rangel, Laureano J. , Vasmatzis, George , Cheville, John C. , Gaitatzes, Athanasios G, Murphy, Stephen J.

Mayo Clinic

Cancer Research | November 10, 2017 | Volume: 77 | Issue: 22 | Pages: 6157-6167

10.1158/0008-5472.can-17-0529 | PMID 29127096 Get It

Abstract TMPRSS2-ERG gene fusions occur in over 50% of prostate cancers, but their impact on clinical outcomes is not well understood. Retention of interstitial genes between TMPRSS2 and ERG has been reported to influence tumor progression in an animal model. In this study, we analyzed the status of TMPRSS2-ERG fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression. Through whole-genome mate pair sequencing, we mapped and classified rearrangements driving ETS family gene fusions in 133 cases of very low-, low-, intermediate-, and high-risk prostate cancer from radical prostatectomy specimens. TMPRSS2-ERG gene fusions were observed in 44% of cases, and over 90% of these fusions occurred in ERG exons 3 or 4. ERG fusions retaining interstitial sequences occurred more frequently in very low-risk tumors. These tumors also frequently displayed ERG gene fusions involving alternative 5′-partners to TMPRSS2, specifically SLC45A3 and NDRG1 and other ETS family genes, which retained interstitial TMPRSS2/ERG sequences. Lastly, tumors displaying TMPRSS2-ERG fusions that retained interstitial genes were less likely to be associated with biochemical recurrence (P = 0.028). Our results point to more favorable clinical outcomes in patients with ETS family fusion-positive prostate cancers, which retain potential tumor-suppressor genes in the interstitial regions between TMPRSS2 and ERG. Identifying these patients at biopsy might improve patient management, particularly with regard to active surveillance. Cancer Res; 77(22); 6157–67. ©2017 AACR.
Assessment of Fluorodeoxyglucose F18–Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules
Deppen, Stephen A. , Mercaldo, Sarah , Blume, Jeffrey D. , Montgomery, Chandler , Vaszar, Laszlo T. , Isbell, James M. , Rickman, Otis B. , Pinkerman, Rhonda, Lambright, Eric S., Nesbitt, Jonathan C., Grogan, Eric L. , Maiga, Amelia Walling , Williamson, Christina

Mayo Clinic

JAMA Surgery | November 8, 2017 | Volume: 153 | Issue: 4 | Pages: 329

10.1001/jamasurg.2017.4495 | PMID 29117314 Get It

Historical epidemiology of hepatitis C virus in select countries—volume 4
Vince, Adriana , Himatt, Sayed , Mohamed, Rosmawati , Opare‐Sem, Ohene , Workneh, A., Njouom, Richard , Ghazzawi, Imad, Abdulla, Maheeba , Kaliaskarova, Kulpash , Owusu‐Ofori, Shirley , Abdelmageed, Marwa , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Estes, Chris , Farag, E., Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Morović, Miro, Murphy, K., Mustapha, B., Nde, H. , Nersesov, Alexander , Ngige, Evelyn, Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, S., Tzeuton, Christian, Ugoeze, S., Vi, R., Wani, Hamid, Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Razavi‐Shearer, Kathryn , Wong, Grace Lai‐Hung , Roberts, Lewis R , Fung, James , Akın, Onur , Blach, Sarah , Chien, Rong‐Nan , Chuang, Wan‐Long , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 8-24

10.1111/jvh.12762 | PMID 29105285 Get It

SummaryDue to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country‐specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Hong Kong to 2.4% in Taiwan, while the largest viraemic populations were in Nigeria (2 597 000 cases) and Taiwan (569 000 cases). Diagnosis, treatment and liver transplant rates varied widely across the countries included in this analysis, as did the availability of reliable data. Addressing data gaps will be critical for the development of future strategies to manage and minimize the disease burden of hepatitis C.
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4
Chan, Henry Lik‐Yuen , Chen, C. J., Omede, O. , Qamish, Jehad Al, Naamani, Khalid Al , Bane, Abate, Tan, S. S. , Simonova, Marieta, Cardenas, I., Derbala, Moutaz , Phillips, Richard Odame , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Busafi, Said A. , Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Chen, Ding‐Shinn , Chen, Pei‐Jer , Cuellar, Diego , Elbardiny, A. A., Farag, Elmoubasher , Gamkrelidze, Ivane , Garcìa, V. , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Hamoudi, Waseem , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee Tak , Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Layden, Jennifer E. , Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching Kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mateva, Lyudmila, Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Mustapha, B., Nersesov, Alexander , Ngige, Evelyn, Njouom, Richard , Njoya, Oudou, Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Reić, Tatjana, Wit, Tobias Rinke de, Ríos, Cielo , Robbins, S., Roberts, Lewis R. , Sanad, S. J., Schmelzer, Jonathan, Sharma, Manik , Su, Tung‐Hung , Sultan, K., Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Nde, H. , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 25-43

10.1111/jvh.12760 | PMID 29105283 Get It

SummaryFactors influencing the morbidity and mortality associated with viremic hepatitis C virus (HCV) infection change over time and place, making it difficult to compare reported estimates. Models were developed for 17 countries (Bahrain, Bulgaria, Cameroon, Colombia, Croatia, Dominican Republic, Ethiopia, Ghana, Hong Kong, Jordan, Kazakhstan, Malaysia, Morocco, Nigeria, Qatar and Taiwan) to quantify and characterize the viremic population as well as forecast the changes in the infected population and the corresponding disease burden from 2015 to 2030. Model inputs were agreed upon through expert consensus, and a standardized methodology was followed to allow for comparison across countries. The viremic prevalence is expected to remain constant or decline in all but four countries (Ethiopia, Ghana, Jordan and Oman); however, HCV‐related morbidity and mortality will increase in all countries except Qatar and Taiwan. In Qatar, the high‐treatment rate will contribute to a reduction in total cases and HCV‐related morbidity by 2030. In the remaining countries, however, the current treatment paradigm will be insufficient to achieve large reductions in HCV‐related morbidity and mortality.
Strategies to manage hepatitis C virus infection disease burden—Volume 4
Chen, Ding‐Shinn , Hamoudi, Waseem , Mustapha, B., Layden, Jennifer E. , Nersesov, Alexander , Reić, Tatjana, Garcìa, V. , Ríos, Cielo , Mateva, Lyudmila, Njoya, Oudou, Al‐Busafi, Said A. , Abdelmageed, Marwa , Abdulla, Maheeba , Adda, Danjuma, Baqali, A. Al, Dweik, N. Al, Ejji, Khalid Al, Ghazzawi, Imad, Kaabi, S. Al, Naamani, Khalid Al , Qamish, Jehad Al, Sadadi, M. Al, Salman, Jameela Al , AlBadri, M., Al‐Romaihi, Hamad Eid , Ampofo, William , Antonov, Krasimir , Anyaike, Chukwuma , Arome, F., Bane, Abate, Blach, Sarah , Borodo, M. M., Brandon, S., Bright, Bisi , Butt, M. T., Cardenas, I., Chan, Henry Lik‐Yuen , Chen, C. J., Chen, Pei‐Jer , Cuellar, Diego , Derbala, M., Elbardiny, A. A., Farag, E., Gamkrelidze, Ivane , Genov, J, Ghandour, Z., Ghuloom, M., Gómez, B. , Gunter, J., Habeeb, J., Hajelssedig, O. , Himatt, Sayed , Hrstić, Irena , Hu, Ching‐Chih , Huang, Chung‐Feng , Hui, Yee‐Tak, Jahis, Rohani, Jelev, Deian, John, Anil K , Kaliaskarova, Kulpash , Kamel, Yasser , Kao, Jia‐Horng , Khamis, Jawad, Khattabi, H., Khoudri, Ibtissam , Конысбекова, А А , Kotzev, Iskren, Lai, Moon Sing, Lao, Wenyu, Lee, M. H., Lesi, Olufunmilayo , Li, M., Loo, Ching‐kong, Lukšić, Boris, Maaroufi, Abderrahmane , Malu, Abraham O., Mitova, R, Mohamed, Rosmawati , Morović, Miro, Murphy, K., Nde, H. , Ngige, Evelyn, Njouom, Richard , Nonković, Diana , Obekpa, Solomon, Oguche, Stephen , Okolo, Eucharia, Omede, O. , Omuemu, C., Opare‐Sem, Ohene , Owusu‐Ofori, Shirley , Phillips, Richard Odame , Prokopenko, Yuriy , Razavi, Homie , Razavi‐Shearer, Devin , Razavi‐Shearer, Kathryn , Redae, Berhane, Wit, Tobias Rinke de, Robbins, S., Roberts, Lewis R. , Sanad, S. J., Sharma, Manik , Simonova, Marieta, Su, Tung‐Hung , Sultan, K., Tan, S. S. , Tchernev, К., Tsang, O. T. Y., Tsang, Simon H. Y., Tzeuton, Christian, Ugoeze, S., Vi, R., Vince, Adriana , Wani, Hamid, Workneh, A., Yacoub, R., Yesmembetov, Kakharman, Youbi, M., Schmelzer, Jonathan, Hui, Yee Tak , Wong, Grace Lai‐Hung , Blach, S , Roberts, Lewis R , Akın, Onur , Chien, Rong‐Nan , Chuang, Wan‐Long , Estes, Chris , Fung, James , Lee, M.-H., Lo, Acy , Ondoa, Pascale , Wit, Tobias F. Rinke de , Robbins, S., Uzochukwu, Benjamin S C. , Wong, Vincent Wai‐Sun , Yuen, Man‐Fung , Lai-Hung Wong, Grace

Mayo Clinic

Journal of Viral Hepatitis | November 4, 2017 | Volume: 24 | Issue: S2 | Pages: 44-63

10.1111/jvh.12759 | PMID 29105286 Get It

SummaryThe hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets—“WHO Targets” (65% reduction in HCV‐related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.